GlassScriptPhysician profile
Wilbur Y Kuo
NPI 1336118900
$14,006.51
in general payments reported to CMS, 2019-2025
60 companies · $2,569 in 2025
The $2,569 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,144 · 2020: $2,311 · 2021: $2,109 · 2022: $1,187 · 2023: $1,363 · 2024: $2,323 · 2025: $2,569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,170 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,170.12 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,414.56 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $1,389.63 | 2020-2025 | |
| Novo Nordisk INC | $1,201.10 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,162.47 | 2019-2025 | |
| Amgen INC. | $868.34 | 2019-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $777.89 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $718.69 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $649.68 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $584.08 | 2019-2022 | |
| Astellas Pharma US INC | $444.22 | 2019-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $372.96 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Antares Pharma, INC. | $363.06 | 2020-2025 | Xyosted, Nocdurna, Tlando |
| Takeda Pharmaceuticals U.S.A., INC. | $324.82 | 2019-2024 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $292.93 | 2019-2025 | Xifaxan |
| Lundbeck LLC | $265.12 | 2021-2025 | Vyepti |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wilbur Kuo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.